Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment

People living alone have a higher risk of cancer mortality. (Cancer)

Integrating an automated screening tool into an electronic health record system showed potential for identifying patients for cancer clinical trials. (Cancer)

CAR T-cell therapy for multiple myeloma proved effective regardless of a patient’s race or ethnicity. (Blood Advances)

Sotio Biotech announced that it will discontinue ongoing trials of interleukin-15 superagonist nanrilkefusp alfa because of insufficient efficacy.

A phase III trial of neoadjuvant therapy with the immunocytokine daromun met the primary endpoint of recurrence-free survival in fully resectable locally advanced melanoma, Philogen and Sun Pharma announced.

A single injection of the HSV-1 oncolytic immunotherapy CAN-3110 led to a median overall survival of 11.6 months in recurrent high-grade glioma. (Nature, Candel Therapeutics)

Preclinical studies suggested that combining the cholesterol-lowering drug lovastatin with a HER2-targeted antibody-drug conjugate may reduce the number of treatment cycles required for HER2-expressing cancers. (Journal of Nuclear Medicine)

Half of patients with advanced non-small cell lung cancer with MET exon 14 skipping mutations responded to the targeted agent ABN401, including six of eight patients with previously untreated disease, Abion announced.

The FDA expanded indications for nivolumab (Opdivo) to include adjuvant treatment for resected stage IIB/C melanoma.

A review of 31 studies of immersive virtual reality suggested the digital technology may help relieve cancer-related pain. (BMJ Supportive & Palliative Care)

The length of a man’s prostatic urethra may influence the likelihood of genitourinary toxicity after radiation therapy for prostate cancer. (Corewell Health, Academic Radiology)

A 3D-printed tumor model might help make cancer treatment faster, less expensive, and less painful. (Nature, University of Waterloo)

Please enable JavaScript to view the

comments powered by Disqus.